Literature DB >> 27026534

Erratum to: Reassessing the risk of natalizumab-associated PML.

Joseph R Berger1,2, Robert J Fox3,4.   

Abstract

Entities:  

Year:  2016        PMID: 27026534     DOI: 10.1007/s13365-016-0431-x

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


× No keyword cloud information.
  2 in total

1.  TLR3 agonism re-establishes CNS immune competence during α4-integrin deficiency.

Authors:  Rehana Z Hussain; Petra C Cravens; Richard Doelger; Brianne Dentel; Emily Herndon; Nicolas Loof; Peter Tsai; Darin T Okuda; Michael K Racke; Olaf Stüve
Journal:  Ann Clin Transl Neurol       Date:  2018-10-30       Impact factor: 4.511

2.  The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives.

Authors:  Rehana Z Hussain; Peter V Sguigna; Annette Okai; Crystal Wright; Mariam Madinawala; Ann D Bass; Gary R Cutter; Navid Manouchehri; Olaf Stuve
Journal:  J Cent Nerv Syst Dis       Date:  2022-08-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.